Abstract
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to the full article PDF.
USD 39.95
Prices may be subject to local taxes which are calculated during checkout
Data availability
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
References
Remberger M, Ackefors M, Berglund S, Blennow O, Dahllof G, Dlugosz A, et al. Improved survival after allogeneic hematopoietic stem cell transplantation in recent years. A single-center study. Biol Blood Marrow Transpl. 2011;17:1688–97.
Malard F, Chevallier P, Guillaume T, Delaunay J, Rialland F, Harousseau JL, et al. Continuous reduced nonrelapse mortality after allogeneic hematopoietic stem cell transplantation: a single-institution’s three decade experience. Bone Marrow Transpl. 2014;20:1217–23.
Sanz MA, Montoro J, Balaguer-Rosello A, Chorao P, Villalba M, Gomez I, et al. Longitudinal outcome over four decades of allogeneic stem cell transplantation: a single center experience. Bone Marrow Transpl. 2024;59:1376–86.
Kurosawa S, Mori A, Tsukagoshi M, Onishi Y, Ohwada C, Mori T, et al. Current status and needs of long-term follow-up clinics for hematopoietic cell transplantation survivors: results of a nationwide survey in Japan. Biol Blood Marrow Transpl. 2020;26:949–55.
Kurosawa S, Yamaguchi T, Mori A, Tsukagoshi M, Okuda I, Ikeda M, et al. Feasibility and usefulness of recommended screenings at long-term follow-up clinics for hematopoietic cell transplant survivors. Support Care Cancer. 2022;30:2767–76.
Nishiwaki S, Miyamura K, Kanda Y, Takanashi M, Uchida N, Fukuda T, et al. A consideration for efficient unrelated hematopoietic stem cell source acquisition-from an experience of Japan. Bone Marrow Transpl. 2020;55:657–60.
Morishima Y, Morishima S, Stevenson P, Kodera Y, Horowitz M, McKallor C, et al. Race and survival in unrelated hematopoietic cell transplantation. Transpl Cell Ther. 2022;28:357.e1–6.
Toya T, Mizuno K, Sakurai M, Kato J, Mori T, Doki N, et al. Differential clinical impact of letermovir prophylaxis according to graft sources: a KSGCT multicenter retrospective analysis. Blood Adv. 2024;8:1084–93.
Dziedzic M, Sadowska-Krawczenko I, Styczynski J. Risk factors for cytomegalovirus infection after allogeneic hematopoietic cell transplantation in malignancies: proposal for classification. Anticancer Res. 2017;37:6551–6.
George B, Kerridge IH, Gilroy N, Huang G, Hertzberg MS, Bradstock KF, et al. A risk score for early cytomegalovirus reactivation after allogeneic stem cell transplantation identifies low-, intermediate-, and high-risk groups: reactivation risk is increased by graft-versus-host disease only in the intermediate-risk group. Transpl Infect Dis. 2012;14:141–8.
Reusser P, Einsele H, Lee J, Volin L, Rovira M, Engelhard D, et al. Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. Blood. 2002;99:1159–64.
Goto T, Tanaka T, Sawa M, Ueda Y, Ago H, Chiba S, et al. Prospective observational study on the first 51 cases of peripheral blood stem cell transplantation from unrelated donors in Japan. Int J Hematol. 2018;107:211–21.
Acknowledgements
We express our gratitude to all the doctors, nurses, and other healthcare professionals at the Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, for providing dedicated patient care.
Author information
Authors and Affiliations
Contributions
S Kurosawa designed the study, collected clinical data, and wrote the manuscript. K Kojo, RY, K Kato, YS, K Kondo, SS, CK, YM, H Hatsusawa, YT, FO, KI, MS, AJ, NS, TT, HS, YN, TK, S Kodaira, TH, NS, KM, NA, TY, TS, and ND provided patient care. S Kurosawa, KH, and YO conducted apheresis and processed the transplant cells. ND supervised the study. All the authors reviewed and approved the final manuscript.
Corresponding author
Ethics declarations
Competing interests
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Ethics approval and consent to participate
All methods were performed in accordance with the relevant guidelines and regulations. The study was approved by the Ethics Committee of Tokyo Metropolitan Komagome Hospital (Approval No. 3416). Informed consent was obtained from all participants.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
About this article
Cite this article
Kurosawa, S., Kojo, K., Yamakawa, R. et al. Improved non-relapse mortality in allogeneic hematopoietic stem cell transplantation: a long-standing multidisciplinary pursuit at a single center. Bone Marrow Transplant 60, 1193–1195 (2025). https://doi.org/10.1038/s41409-025-02625-y
Received:
Revised:
Accepted:
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s41409-025-02625-y
